Cognition announces Phase 2 ‘SHIMMER’ study to be presented at ILBDC
Cognition Therapeutics (CGTX) announced that JamesGalvin, MD, MPH will present topline results from the ‘SHIMMER’ study of zervimesine in ...
Nasdaq5d
Cognition Therapeutics Reports Positive Topline Results of Zervimesine in SHIMMER Study for Dementia with Lewy Bodies
Dr. Galvin emphasized that these results might ... announced that James E. Galvin, MD, MPH will present topline results from the ‘SHIMMER’ study of zervimesine (CT1812) in dementia with ...